- 专利标题： HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF
-
申请号： US17266419申请日： 2019-08-06
-
公开(公告)号： US20210292428A1公开(公告)日： 2021-09-23
- 发明人: Mitchell Ho , Nan Li , Bryan D. Fleming
- 申请人： The U.S.A., as represented by the Secretary, Department of Health and Human Services
- 申请人地址： US MD Bethesda
- 专利权人： The U.S.A., as represented by the Secretary, Department of Health and Human Services
- 当前专利权人： The U.S.A., as represented by the Secretary, Department of Health and Human Services
- 当前专利权人地址： US MD Bethesda
- 国际申请： PCT/US2019/045338 WO 20190806
- 主分类号： C07K16/30
- IPC分类号： C07K16/30 ; C07K14/725 ; A61K47/68 ; G01N33/574 ; C12N15/86 ; A61P35/00
摘要：
Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.
公开/授权文献
信息查询
